[1]Sadelain M., Rivière I., Riddell S. Therapeutic T-cell engineering. Nature. 2017;545:423-431. 7655
[2]June C.H., Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64-73. 1
[3]Locke F.L., Ghobadi A., Jacobson C.A. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31-42. 1
[4]Schuster S.J., Bishop M.R., Tam C.S. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45-56. 1
[5]Maude S.L., Laetsch T.W., Buechner J. Tisagenlecleucel in children and young adults with B-cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439-448. 5
[6]Shah N.N., Fry T.J. Mechanisms of resistance to CAR T-cell therapy. Nat Rev Clin Oncol. 2019;16:372-385. 6
[7]Neelapu S.S., Rossi J.M., Jacobson C.A. CD19-Loss with preservation of other B-cell lineage features in patients with large B-cell lymphoma who relapsed post axi-cel. Blood. 2019;134:203-1203. Suppl_1
[8]Sotillo E., Barrett D.M., Black K.L. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CAR T-19 immunotherapy. Cancer Discov. 2015;5:1282-1295. 12
[9]Gardner R., Wu D., Cherian S. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR T-cell therapy. Blood. 2016;127:2406-2410. 20
[10]Hamieh M., Dobrin A., Cabriolu A. CAR T-cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568:112-116. 7750
[11]Fischer J., Paret C., El Malki K. CD19 Isoforms enabling resistance to CAR T-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40:187-195. 5
[12]Ruella M., Xu J., Barrett D.M. Induction of resistance to chimeric antigen receptor T-cell therapy by transduction of a single leukemic B-cell. Nat Med. 2018;1.
[13]Singh N., Lee Y.G., Shestova O. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10:552-567. 4
[14]Dufva O., Koski J., Maliniemi P. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2020;135:597-609. 9
[15]Joyce J.A., Fearon D.T. T-cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74-80. 6230
[16]Galon J., Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197-218. 3
[17]Rossi J.M., Galon J., Chang E. Abstract CT153: pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1. Cancer Res. 2019;79:CT153. Suppl_13
[18]Mueller K.T., Waldron E., Grupp S.A. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24:6175-6184. 24
[19]Park J.H., Rivière I., Gonen M. Long term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449-459. 5
[20]Neelapu S.S., Locke F.L., Bartlett N.L. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-2544. 26
[21]Kawalekar O.U., O’Connor R.S., Fraietta J.A. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T-cells. Immunity. 2016;44:380-390. 2
[22]Lee D.W., Santomasso B.D., Locke F.L. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25:625-638. 4
[23]June C.H., O’Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T-cell immunotherapy for human cancer. Science. 2018;359:1361-1365. 6382
[24]Hunter B.D., Jacobson C.A. CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;11.
[25]Sommermeyer D., Hudecek M., Kosasih P.L. Chimeric antigen receptor-modified T-cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity . Leukemia. 2016;30:492-500. in vivo2
[26]Weber E.W., Maus M.V., Mackall C.L. The emerging landscape of immune cell therapies. Cell. 2020;181:46-62. 1
[27]Fraietta J.A., Nobles C.L., Sammons M.A. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T-cells. Nature. 2018;558:307-312. 7709
[28]Ghorashian S., Kramer A.M., Onuoha S. Enhanced CAR T-cell expansion and prolonged persistence in pediatric patients with all treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408-1414. 9
[29]Feucht J., Sun J., Eyquem J. Calibration of CAR activation potential directs alternative T-cell fates and therapeutic potency. Nat Med. 2019;25:82-88. 1
[30]Eyquem J., Mansilla-Soto J., Giavridis T. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113-117. 7643
[31]Chen J., López-Moyado I.F., Seo H. NR4A transcription factors limit CAR T-cell function in solid tumours. Nature. 2019;567:530-534. 7749
[32]Lynn R.C., Weber E.W., Sotillo E. c-Jun overexpression in CAR T-cells induces exhaustion resistance. Nature. 2019;576:293-300. 7786
[33]Ruella M., Kenderian S.S., Shestova O. The addition of the BTK inhibitor ibrutinib to Anti-CD19 chimeric antigen receptor T-cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2016 01;22:2684-2696. 11
[34]Gauthier J., Hirayama A.V., Purushe J. Feasibility and efficacy of CD19-targeted CAR T-cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020.
[35]Shah N.N., Maatman T., Hari P., Johnson B. Multi targeted CAR T-cell therapies for B-cell malignancies. Front Oncol. 2019;9:146.
[36]Kuhn N.F., Purdon T.J., van Leeuwen D.G. CD40 ligand-modified chimeric antigen receptor T-cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35:473-488. 3
[37]Curran K.J., Seinstra B.A., Nikhamin Y. Enhancing antitumor efficacy of chimeric antigen receptor T-cells through constitutive CD40L expression. Mol Ther J Am Soc Gene Ther. 2015;23:769-778. 4
[38]Lai J., Mardiana S., House I.G. Adoptive cellular therapy with T-cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol. 2020.
[39]Stephan M.T., Ponomarev V., Brentjens R.J. T-cell encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13:1440-1449. 12
[40]Jacobson C, Westin J, Miklos D. Phase 1/2 primary analysis of ZUMA-6: axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL). American Association for Cancer Research Virtual Annual Meeting I. 2020. Accessible from: bit.ly/3eZDfb4.
[41]Rafiq S., Yeku O.O., Jackson H.J. Targeted delivery of a PD-1-blocking scFv by CAR T-cells enhances anti-tumor efficacy . Nat Biotechnol. 2018;36:847-856. in vivo9
[42]Cherkassky L., Morello A., Villena-Vargas J. Human CAR T-cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130-3144. 8
[43]Sakemura R., Cox M.J., Hansen M.J. Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T-cell therapy in multiple myeloma. Blood. 2019;134. Suppl_1https://doi.org/10.1182/blood-2019-123277
[44]Ying Z., Huang X.F., Xiang X. A safe and potent anti-CD19 CAR T-cell therapy. Nat Med. 2019;25:947-953. 6
[45]Brudno J.N., Lam N., Vanasse D. Safety and feasibility of anti-CD19 CAR T-cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26:270-280. 2
[46]Mestermann K., Giavridis T., Weber J. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T-cells. Sci Transl Med. 2019;11. 499